



## Synthesis and biological evaluation of epothilone A dimeric compounds

Daniele Passarella<sup>a,\*</sup>, Daniela Comi<sup>a</sup>, Graziella Cappelletti<sup>b</sup>, Daniele Cartelli<sup>b</sup>, Juerg Gertsch<sup>c</sup>, Ana R. Quesada<sup>d,†</sup>, Jurgen Borlak<sup>e,†</sup>, Karl-Heinz Altmann<sup>c,†</sup>

<sup>a</sup> Dipartimento di Chimica Organica e Industriale, Università degli Studi di Milano, Via Venezian 21, Italy

<sup>b</sup> Dipartimento di Biologia, Università degli Studi di Milano, Via Celoria 26, 20133 Milano, Italy

<sup>c</sup> ETH Zurich, Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, HCI H 405, 8093 Zurich, Switzerland

<sup>d</sup> Departamento de Biología Molecular y Bioquímica, Universidad de Málaga, E-29071 Málaga, Spain

<sup>e</sup> Fraunhofer Institute of Toxicology and Experimental Medicine Medical School of Hannover, Nikolai-Fuchs-Str 1, 30625 Hannover, Germany

### ARTICLE INFO

#### Article history:

Received 20 June 2009

Revised 11 September 2009

Accepted 17 September 2009

Available online 20 September 2009

#### Keywords:

Epothilone A

Tubulin polymerization

Inhibition of angiogenesis

### ABSTRACT


The preparation and biological evaluation of a novel series of dimeric epothilone A derivatives (**1–6**) are described. Two types of diacyl spacers were introduced to establish the various dimeric epothilone A constructs. The effect of these compounds on tubulin polymerization and their cytotoxicity against four different cancer cell lines are reported. Several of the newly synthesized compounds inhibit endothelial cell differentiation and endothelial cell migration that are key steps of the angiogenic process.

© 2009 Elsevier Ltd. All rights reserved.

### 1. Introduction

Substances that are able to interfere with the tubulin-microtubule system, either through inhibition of tubulin polymerization or through microtubule stabilization, are important anticancer agents. Prominent examples are the vinca alkaloids (which act as tubulin polymerization inhibitors) or the diterpenoid alkaloid taxol and its semi-synthetic derivative docetaxel (which are microtubule stabilizers), all of which are indispensable components of modern cancer chemotherapy regimens.<sup>1</sup> The most recent addition to the clinical arsenal of tubulin inhibitors is the lactam analog of the bacterial natural product epothilone B<sup>2</sup> (**Epo B**, Fig. 1), which has been approved for clinical use by the US FDA in late 2007 under the trade name Ixempra<sup>®</sup> (generic name: ixabepilone).<sup>3</sup> In addition to their growth-inhibitory and apoptosis-inducing activity, some tubulin inhibitors have recently been shown to target the vascular system of tumors,<sup>4</sup> thereby causing vasculature recession (induction of apoptosis by a classical antiangiogenic mechanism) or vasculature ‘normalization’.<sup>5</sup> Vasculature normalization facilitates and enhances tumor cell penetration by anticancer drugs, thus offering the opportunity for extensive tumor kill by appropriate drug combinations. As a consequence, the identification of new tubulin modulators<sup>6</sup> remains an important challenge in anticancer drug discovery and the use of well known tubulin-interacting agents

as scaffolds is a represents reasonable approach towards this goal. In this context, we have been intrigued by a dimeric epothilone analog (**Epo-Dim**, Fig. 1) that has been reported by Nicolaou et al.<sup>7</sup> several years ago as an undesired side product in the course of the target-oriented synthesis of a series of side chain-modified epothilones. Although no specific data were provided for this analog,<sup>7</sup> the compound is stated to exhibit remarkable tubulin-poly-




**Figure 1.** Epothilones A and B. Structure of the dimeric epothilone analog **Epo-Dim** described by Nicolaou et al. (Ref. 7).

\* Corresponding author. Tel.: +39 02 50314081; fax: +39 02 50314078.

E-mail address: [Daniele.Passarella@unimi.it](mailto:Daniele.Passarella@unimi.it) (D. Passarella).

† Contributed equally as senior authors.



Scheme 1. General preparation of derivatives 1–6.

merizing and antiproliferative activity. Building on these earlier findings we have now synthesized a set of A epothilone dimers that are more readily accessible than **Epo-Dim** and we have investigated the *in vitro* biological properties of these new epothilone derivatives (Scheme 1).<sup>8</sup>

## 2. Results and discussion

### 2.1. Chemistry

The presence of two hydroxyl groups in the epothilone macrocycle offered an opportunity for the direct introduction of a spacer moiety between two epothilone monomers. Assuming the OH-group on C3 to be sterically more hindered, we felt that the acylation of C7–OH should be feasible with reasonable selectivity and thus provide C7 linked dimers as the major products of the reaction of **Epo A** with activated dicarboxylic acids.<sup>9</sup> While being aware of the potential *in vivo* lability of the ester function our initial objective was to prepare a number of prototypical dimers in the simplest way possible and to evaluate these compounds in tubulin polymerization assays. Thus reaction of **Epo A** with six different dicarboxylic acids in the presence of DCC and DMAP (Scheme 1) gave the corresponding products (1–6) with excellent regioselectivity. The latter compensated at least

partially, for the low to moderate yields obtained in the esterification reactions (25–40%). Esterification of the C7–OH group in the derivatives isolated (rather than C3–OH) was demonstrated by NMR spectroscopy. The spectra of 1–6 exhibit a single set of signals for the epothilone unit with chemical shifts that are similar to those in the spectrum of **Epo A**, except for the signal for H-7, which is down-shifted to  $\delta$  5.37–5.44 (**Epo A**  $\delta$  3.80). All compounds appeared sufficiently stable chemically under the conditions of the biological experiments.

### 2.2. Influence on tubulin polymerization

In order to assess the interaction of compounds 1–6 with the tubulin/microtubule system, they were tested in an *in vitro* tubulin polymerization assay at fixed concentrations of 5 and 10  $\mu$ M. As illustrated by the data in Table 1, **Epo A** at these concentrations induces almost complete assembly of soluble tubulin into microtubule polymers. In contrast, no physically meaningful tubulin assembly could be detected for any of the dimeric analogs 1–6 under the same experimental conditions. While it cannot be excluded that tubulin polymerization might be detectable under a different set of experimental conditions, it is clear from the data in Table 1 that dimers 1–6 are substantially less potent inducers of tubulin polymerization than **Epo A** *in vitro* (if any).

**Table 1**  
Biological evaluation of compounds 1–6

Compound	% Tubulin polym. <sup>a</sup>		A-549	MCF-7	HT-1080	$\beta$ D10 <sup>b</sup>	BAE	Tubes	Migration
	(10 $\mu$ M)	(5 $\mu$ M)						MIC <sup>d</sup> (nM)	
<b>Epo A</b>	99.8 $\pm$ 0.4	92.2 $\pm$ 2.3	2.6 $\pm$ 0.23	2.5 $\pm$ 0.29	1.3 $\pm$ 0.5	70	0.7 $\pm$ 0.4	5	5
<b>1</b>	1 $\pm$ 0.5	0.3 $\pm$ 0.4	319 $\pm$ 21	357 $\pm$ 44	290 $\pm$ 98	1000	29 $\pm$ 3	100	50
<b>2</b>	0.2 $\pm$ 0.4	0 $\pm$ 0.3	367 $\pm$ 18	379 $\pm$ 20	43 $\pm$ 18	3.3	111 $\pm$ 73	50	100
<b>3</b>	0.2 $\pm$ 0.6	0.5 $\pm$ 0.7	383 $\pm$ 30	432 $\pm$ 17	71 $\pm$ 15	2000	133 $\pm$ 30	100	100 <sup>*</sup>
<b>4</b>	0.7 $\pm$ 0.4	0.2 $\pm$ 0.4	405 $\pm$ 27	412 $\pm$ 18	69 $\pm$ 22	70,500	40 $\pm$ 10	100	100
<b>5</b>	0.3 $\pm$ 0.5	0.7 $\pm$ 0.5	316 $\pm$ 17	321 $\pm$ 28	17 $\pm$ 13	2500	20 $\pm$ 13	100	100
<b>6</b>	0.6 $\pm$ 0.5	0.1 $\pm$ 0.7	956 $\pm$ 43	1033 $\pm$ 39	13 $\pm$ 3	5020	39 $\pm$ 8	50	100 <sup>*</sup>

<sup>a</sup> Partial inhibition.

<sup>a</sup> Polymerization was monitored at a fixed compound concentration of 5 or 10  $\mu$ M by following the increase in absorption at 340 nm.

<sup>b</sup> Cells from lung tumors of double c-myc and c-raf transgenic mice.

<sup>c</sup> Compound concentration, in nM, that causes 50% inhibition of the control cell growth, data are means  $\pm$  SD of at least three independent experiments with triplicate samples each.

<sup>d</sup> Minimal inhibitory concentration of compounds 1–6 (MIC) on BAE (bovine aortic endothelial) cell differentiation (tube formation) or migration. The different assay was carried out in the presence of different concentrations of **Epo A** and dimers 1–6 as described in Section 4. Migration assay was carried out in the presence of different concentrations of epothilone A and related compounds as described in Section 4.


Given the chemical stability of all the dimeric compounds **1–6** under the conditions of a cell culture assay and in light of a noticeably improved solubility (compared with **Epo A**) the antiproliferative activity of these compounds was evaluated against a series of cancer cells.

### 2.3. Cytotoxicity


The anticancer activities of the new compounds were examined in three different human cancer cell lines, namely A549 (lung cancer), MCF7 (breast cancer), and HT1080 (fibrosarcoma) and in one transformed mouse cell line that is derived from lung tumors of double c-myc and c-raf transgenic mice ( $\beta$ D10)<sup>10</sup> (Table 1). With one exception all compounds investigated were found to be less active than the parent compound **Epo A**, thus reflecting the reduced ability of the dimeric analogs to induce tubulin polymerization in vitro. It remains to be determined, whether the observed cellular activity is in fact associated with the dimers as such or whether it may be a consequence of (partial) enzyme-mediated ester hydrolysis (either in the cell culture medium or inside the cells) and the ensuing release of free **Epo A**. As an exception, the stem cell line  $\beta$ D10 appeared to be more sensitive to **2** than to **Epo A**. The reason for this behavior is unclear at this point.

### 2.4. Antiangiogenic activity

Angiogenesis involves local proliferation of endothelial cells.<sup>11</sup> Therefore, we also investigated the ability of **Epo A** and dimers



**Figure 2.** Effects of **Epo A** and dimeric derivatives on endothelial cells: (a) control; (b) **Epo A**, 5 nM; (c) **1**, 100 nM; (d) **2**, 100 nM; (e) **3**, 100 nM; (f) **4**, 100 nM; (g) **5**, 100 nM; (h) **6**, 50 nM.



**Figure 3.** Effect of **Epo A** and dimeric derivatives on endothelial cell migration: (a) control; (b) **Epo A**, 5 nM; (c) **1**, 50 nM; (d) **2**, 100 nM; (e) **3**, 100 nM; (f) **4**, 100 nM; (g) **5**, 100 nM; (h) **6**, 100 nM.

**1–6** to inhibit the growth of endothelial cells. As illustrated by the  $IC_{50}$  values shown in Table 1, the dimeric epothilone analogs inhibit endothelial cell growth at submicromolar concentrations. But they are clearly less potent than the parent compound **Epo A**. Comparison of these results with those obtained with tumor cells (previous paragraph) demonstrates that the inhibitory effect is not endothelial cell specific in the case of compounds **2–6** and **Epo A**. The data suggest, however, that compound **1** could present a higher cell growth inhibitory activity for endothelial cells when compared to that on tumor cells.

The final event during angiogenesis is the organization of endothelial cells into a three-dimensional network of tubes. In vitro, endothelial cells plated on Matrigel align themselves forming cords, already evident a few hours after plating. Figure 2b shows that 5 nM **Epo A** was able to completely inhibit the BAE cell alignment and cord formation. Dimerization of **Epo A** decreases the endothelial morphogenesis inhibitory activity. An inhibition of endothelial morphogenesis on Matrigel was obtained with 50 nM compound **6**, or with 100 nM compounds **1–5** (Fig. 2c–h). Angiogenesis involves the acquisition by endothelial cells of the capability to migrate through the extracellular matrix, degrade the basement membrane and, in general, to remodel the extracellular matrix. Our results, presented in Figure 3a, show that 5 nM **Epo A** produced a significant inhibition of the migratory capability of BAE cells. As shown in Figure 3b–h, a significant effect on BAE cells migration was observed in the presence of compound **1** (50 nM) or compounds **2–6** (100 nM).

### 3. Conclusions

Our results indicate that several **Epo A** related dimeric compounds inhibit endothelial cell differentiation and endothelial cell migration, which are key steps of the angiogenic process, at non-toxic concentrations. The discovery that these compounds

interfere with several functions of activated endothelial cells suggests that they could be of interest for the development of new agents for the treatment of angiogenesis-related diseases.

## 4. Experimental section

### 4.1. General

Thin-layer chromatography (TLC) was performed on Merck pre-coated 60F254 plates. Reactions were monitored by TLC on silica gel, with detection by UV light (254 nm) or by charring with sulfuric acid. Flash chromatography was performed using Silica gel (240–400 mesh, Merck).  $^1\text{H}$  NMR spectra were recorded with Bruker 200, 300 and 400 MHz spectrometers using chloroform- $d$  ( $\text{CDCl}_3$ ) and methanol- $d_4$  ( $\text{CD}_3\text{OD}$ ). Chemical shifts are reported in parts per million ( $\delta$ ) downfield from tetramethylsilane (TMS) as internal standard. EI mass spectra were recorded at an ionizing voltage of 6 Kev on a VG 70–70 EQ. ESI mass spectra were recorded on FT-ICR APEX<sup>II</sup> (Bruker Daltonics). All reactions were carried out in dry solvents.

Cell culture media were purchased from Gibco (Grand Island, NY, USA) and Biowhittaker (Walkersville, MD, USA). Fetal bovine serum (FBS) was a product of Harlan-Seralab (Belton, UK). Matrigel was purchased from Becton Dickinson (Bedford, MA, USA). Supplements and other chemicals not listed in this section were obtained from Sigma Chemicals Co. (St. Louis, Mo., USA). Plastics for cell culture were supplied by NUNC (Roskilde, Denmark). Epothilone A and related compounds (Fig. 1) were dissolved in dimethylsulfoxide (DMSO) at a concentration of 10 mM and stored at  $-20^\circ\text{C}$  until use. Bovine aortic endothelial (BAE) cells were obtained by collagenase digestion and maintained in Dulbecco's modified Eagle's medium containing glucose (1 g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50  $\mu\text{g}/\text{mL}$ ), and amphoterycin (1.25  $\mu\text{g}/\text{mL}$ ) (DMEM) supplemented with 10% FBS (DMEM/10% FBS). Human fibrosarcoma HT1080 cells were obtained from the ATCC and maintained in DMEM containing glucose (4.5 g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50  $\mu\text{g}/\text{mL}$ ), and amphoterycin (1.25  $\mu\text{g}/\text{mL}$ ) supplemented with 10% FBS.

### 4.2. General procedure for preparation of compounds 1–6

DMAP (0.05 mmol), epothilone (0.1 mmol) and DCC (0.15 mmol) were added to a solution of diacid (0.05 mmol) in  $\text{CH}_2\text{Cl}_2$  dry at room temperature. The mixture was stirred for 6–8 h then concentrated under reduced pressure. The crude residue was purified by flash chromatography (silica gel, AcOEt/hexane 3:2) to give the dimeric compounds. Yields: 25–40%.

**Epothilone A:**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  6.99 (1H, s), 6.61 (1H, s), 5.44 (1H, dd,  $J = 2.5, 8.7$  Hz), 4.21–4.19 (1H, m), 3.95 (1H, br s), 3.80 (1H, t,  $J = 4.3$  Hz), 3.50 (1H, br s), 3.27–3.21 (1H, m), 3.06–3.02 (1H, m), 2.94–2.90 (1H, m), 2.71 (3H, s), 2.66 (1H, br s), 2.55 (1H, dd,  $J = 14.5, 10.5$  Hz), 2.42 (1H, dd,  $J = 14.5, 3.2$  Hz), 2.17–2.12 (1H, m), 2.11 (3H, s), 1.93–1.85 (1H, td,  $J = 15.1, 8.4$  Hz), 1.78–1.72 (2H, m), 1.57–1.41 (5H, m), 1.38 (3H, s), 1.18 (3H, d,  $J = 6.8$  Hz), 1.11 (3H, s), 1.01 (3H, d,  $J = 7.0$  Hz);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  218.8 (1C), 171.1 (1C), 165.8 (1C), 152.4 (1C), 138.2 (1C), 120.4 (1C), 116.8 (1C), 77.2 (1C), 75.2 (1C), 73.8 (1C), 58.0 (1C), 55.2 (1C), 44.0 (1C), 39.6 (1C), 36.9 (1C), 32.2 (1C), 31.2 (1C), 27.8 (1C), 24.1 (1C), 22.2 (1C), 21.0 (1C), 19.6 (1C), 17.7 (1C), 16.3 (1C), 14.6 (1C).

**Compound 1:**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.01 (2H, s), 6.67 (2H, s), 5.52 (2H, dd,  $J = 6.5, 2.1$  Hz), 5.44 (2H, dd,  $J = 1.7, 8.9$  Hz), 4.17–4.12 (2H, m), 3.5–3.4 (2H, dd,  $J = 9.83, 6.99$  Hz), 3.12–3.05 (2H, m), 2.95–2.88 (2H, m), 2.73 (6H, s), 2.60–2.55 (4H, m), 2.15 (6H, s), 2.13–2.10 (2H, m), 2.00–1.98 (2H, m), 1.82–1.79 (2H, m), 1.66–

1.55 (8H, m), 1.40 (8H, s), 1.30–1.26 (6H, s), 1.13 (6H, s), 1.10 (6H, d,  $J = 6.8$  Hz), 0.96 (6H, d,  $J = 6.8$  Hz);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  216.1 (2C), 170.3 (2C), 168.7 (2C), 164.9 (2C), 152.1 (2C), 136.8 (2C), 119.8 (2C), 116.3 (2C), 80.2 (2C), 76.0 (2C), 73.9 (2C), 57.3 (2C), 53.7 (2C), 52.3 (2C), 43.8 (2C), 38.4 (2C), 34.4 (2C), 30.8 (2C), 29.2 (4C), 26.2 (2C), 24.1 (2C), 22.2 (2C), 20.8 (2C), 18.9 (2C), 17.4 (2C), 16.6 (2C), 15.5 (2C); Anal. Calcd for  $\text{C}_{56}\text{H}_{80}\text{N}_2\text{O}_{14}\text{S}_4$ : C, 59.34; H, 7.11; N, 2.47. Found: C, 59.38; H, 7.15; N, 2.43.  $[\alpha]_{\text{D}}^{25} = -2.2$  (c 0.85,  $\text{CHCl}_3$ ); HRESI positive MS: Anal. Calcd for  $\text{C}_{56}\text{H}_{80}\text{N}_2\text{O}_{14}\text{S}_4\text{Na}^+$ , 1155.43846; found 1155.43862.

**Compound 2:**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.00 (2H, s), 6.64 (2H, s), 5.50 (2H, br d,  $J = 4.7$  Hz), 5.41 (2H, d,  $J = 9.1$  Hz), 4.16–4.11 (2H, m), 3.44–3.36 (2H, m), 3.16–3.06 (2H, m), 2.98 (4H, t,  $J = 7.1$  Hz), 2.93–2.90 (2H, m), 2.80 (8H, t,  $J = 7.0$  Hz), 2.72 (6H, s), 2.60–2.51 (4H, m), 2.13 (6H, s), 2.07–1.94 (4H, m), 1.80–1.71 (2H, m), 1.68–1.53 (8H, m), 1.39 (6H, s), 1.40–1.35 (2H, m), 1.29–1.24 (2H, m), 1.12 (6H, s), 1.09 (6H, d,  $J = 6.7$  Hz), 0.95 (6H, d,  $J = 6.7$  Hz);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  217.2 (2C), 171.8 (2C), 171.1 (2C), 165.5 (2C), 152.8 (2C), 137.2 (2C), 120.7 (2C), 117.0 (2C), 79.7 (2C), 76.7 (2C), 74.7 (2C), 58.0 (2C), 54.5 (2C), 53.0 (2C), 44.4 (2C), 39.0 (2C), 35.0 (2C), 34.8 (2C), 34.0 (2C), 32.0 (2C), 29.9 (2C), 26.9 (2C), 24.7 (2C), 22.9 (2C), 21.0 (2C), 19.7 (2C), 18.2 (2C), 16.3 (2C), 16.2 (2C); Anal. Calcd for  $\text{C}_{58}\text{H}_{84}\text{N}_2\text{O}_{14}\text{S}_4$ : C, 59.97; H, 7.29; N, 2.41. Found: C, 59.99; H, 7.31; N, 2.43.  $[\alpha]_{\text{D}}^{25} = -2.96$  (c 0.455,  $\text{CHCl}_3$ ); HRESI positive MS: Anal. Calcd for  $\text{C}_{58}\text{H}_{84}\text{N}_2\text{O}_{14}\text{S}_4\text{Na}^+$ , 1183.46976; found 1183.46837.

**Compound 3:**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.05 (2H, s), 6.63 (2H, s), 5.51 (2H, dd,  $J = 2.3, 6.8$  Hz), 5.38 (2H, dd,  $J = 1.9, 8.7$  Hz), 4.14–4.11 (2H, m), 3.42–3.38 (2H, m), 3.10–3.06 (2H, m), 2.93–2.90 (2H, m), 2.78 (4H, t,  $J = 7.0$  Hz), 2.72 (6H, s), 2.61–2.54 (4H, m), 2.50 (4H, t,  $J = 7.3$  Hz), 2.15 (6H, s), 2.15–2.10 (2H, m), 2.06 (4H, t,  $J = 7.1$  Hz), 1.99–1.95 (2H, m), 1.80–1.76 (2H, m), 1.65–1.55 (8H, m), 1.38 (6H, s), 1.33–1.18 (4H, m), 1.13 (6H, s), 1.08 (6H, d,  $J = 6.9$  Hz), 0.94 (6H, d,  $J = 6.8$  Hz);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  216.2 (2C), 172.3 (2C), 170.4 (2C), 164.3 (2C), 152.2 (2C), 136.6 (2C), 120.0 (2C), 116.3 (2C), 78.4 (2C), 76.1 (2C), 73.9 (2C), 57.3 (2C), 53.8 (2C), 52.3 (2C), 43.7 (2C), 38.5 (2C), 38.0 (2C), 34.5 (2C), 32.6 (2C), 31.8 (2C), 29.4 (2C), 26.3 (2C), 24.4 (2C), 24.1 (2C), 22.1 (2C), 20.4 (2C), 19.0 (2C), 17.5 (2C), 15.5 (2C), 15.3 (2C); Anal. Calcd for  $\text{C}_{60}\text{H}_{88}\text{N}_2\text{O}_{14}\text{S}_4$ : C, 60.58; H, 7.46; N, 2.35. Found: C, 60.61; H, 7.48; N, 2.38.  $[\alpha]_{\text{D}}^{25} = -3.8$  (c 0.554,  $\text{CHCl}_3$ ); HRESI positive MS: Anal. Calcd for  $\text{C}_{60}\text{H}_{88}\text{N}_2\text{O}_{14}\text{S}_4\text{Na}^+$ , 1211.50106; found 1211.50400.

**Compound 4:**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  6.98 (2H, s), 6.63 (2H, s), 5.51 (2H, dd,  $J = 2.2, 7.1$  Hz), 5.38 (2H, dd,  $J = 1.9, 8.7$  Hz), 4.15–4.09 (2H, br m), 3.41–3.38 (2H, m), 3.10–3.05 (2H, m), 2.93–2.89 (2H, m), 2.72 (6H, s), 2.58–2.55 (4H, m), 2.40 (6H, br m), 2.12 (6H, s), 2.11–2.07 (2H, m), 2.01–1.93 (2H, m), 1.80–1.54 (12H, m), 1.45–1.40 (2H, m), 1.38 (6H, s), 1.32–1.17 (2H, m), 1.13 (6H, s), 1.07 (6H, d,  $J = 6.9$  Hz), 0.94 (6H, d,  $J = 6.8$  Hz);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  216.4 (2C), 172.8 (2C), 170.5 (2C), 165.5 (2C), 152.6 (2C), 120.5 (2C), 116.3 (2C), 78.3 (2C), 76.0 (2C), 73.9 (2C), 71.7 (2C), 57.4 (2C), 53.9 (2C), 52.4 (2C), 43.7 (2C), 38.4 (2C), 34.3 (2C), 33.9 (2C), 31.4 (2C), 29.6 (2C), 26.2 (2C), 24.9 (2C), 24.1 (2C), 22.2 (2C), 20.5 (2C), 19.1 (2C), 17.6 (2C), 15.7 (2C), 15.5 (2C); Anal. Calcd for  $\text{C}_{58}\text{H}_{84}\text{N}_2\text{O}_{14}\text{S}_2$ : C, 63.48; H, 7.72; N, 2.55. Found: C, 63.51; H, 7.70; N, 2.51.  $[\alpha]_{\text{D}}^{25} = -4.3$  (c 0.36,  $\text{CHCl}_3$ ); HRESI positive MS: Anal. Calcd for  $\text{C}_{58}\text{H}_{84}\text{N}_2\text{O}_{14}\text{S}_2\text{Na}^+$ , 1119.52562; found 1119.52719.

**Compound 5:**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  6.98 (2H, s), 6.62 (2H, s), 5.50 (2H, dd,  $J = 1.7, 6.9$  Hz), 5.37 (2H, dd,  $J = 1.7, 8.8$  Hz), 4.13–4.09 (2H, br m), 3.39 (2H, dd,  $J = 6.9, 8.6$  Hz), 3.10–3.07 (2H, m), 2.92–2.89 (2H, m), 2.72 (6H, s), 2.57–2.55 (4H, m), 2.35 (4H, t,  $J = 7.41$  Hz), 2.14 (6H, s), 2.12–2.08 (2H, m), 1.99–1.92 (2H, m), 1.75–1.53 (14H, m), 1.45–1.39 (6H, m), 1.38 (6H, s), 1.23–1.17 (2H, m), 1.13 (6H, s), 1.08 (6H, d,  $J = 6.8$  Hz), 0.94 (6H, d,



$J = 6.8$  Hz);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  216.2 (2C), 173.0 (2C), 170.4 (2C), 165.5 (2C), 152.3 (2C), 136.6 (2C), 120.1 (2C), 116.3 (2C), 78.1 (2C), 76.2 (2C), 73.9 (2C), 57.3 (2C), 53.9 (2C), 52.3 (2C), 43.8 (2C), 38.5 (2C), 34.5 (2C), 34.3 (2C), 31.5 (2C), 29.6 (2C), 28.8 (2C), 26.3 (2C), 24.8 (2C), 24.1 (2C), 22.1 (2C), 20.5 (2C), 19.0 (2C), 17.5 (2C), 15.5 (2C), 15.4 (2C); Anal. Calcd for  $\text{C}_{60}\text{H}_{88}\text{N}_2\text{O}_{14}\text{S}_2$ : C, 64.03; H, 7.88; N, 2.55. Found: C, 64.06; H, 7.87; N, 2.51. MS-ESI (MeOH)  $m/z$  (%) 1147.8 (100) ( $\text{MNa}^+$ ); 1126.0 (26) ( $\text{MH}^+$ );  $[\alpha]_{\text{D}}^{25} = -6.8$  (c 0.54,  $\text{CHCl}_3$ ); HRESI positive MS: Anal. Calcd for  $\text{C}_{60}\text{H}_{88}\text{N}_2\text{O}_{14}\text{S}_2\text{Na}^+$ , 1147.55692; found 1147.55527.

**Compound 6:**  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  6.99 (2H, s), 6.64 (2H, s), 5.52 (2H, br d), 5.38 (2H, dd,  $J = 1.7, 8.8$  Hz), 4.14–4.09 (2H, br m), 3.41–3.37 (2H, m), 3.10–3.06 (2H, m), 2.93–2.92 (2H, m), 2.73 (6H, s), 2.58–2.56 (4H, m), 2.35 (4H, t,  $J = 7.4$  Hz), 2.15 (6H, s), 2.10–2.08 (2H, m), 2.00–1.93 (2H, m), 1.75–1.54 (14H, m), 1.39 (6H, s), 1.36–1.18 (12H, m), 1.14 (6H, s), 1.08 (6H, d,  $J = 6.9$  Hz), 0.95 (6H, d,  $J = 6.8$  Hz);  $^{13}\text{C}$  NMR (100.6 MHz,  $\text{CDCl}_3$ )  $\delta$  216.2 (2C), 173.1 (2C), 170.4 (2C), 165.3 (2C), 153.7 (2C), 135.8 (2C), 120.1 (2C), 116.3 (2C), 78.4 (2C), 76.2 (2C), 73.9 (2C), 57.3 (2C), 53.9 (2C), 52.3 (2C), 43.9 (2C), 38.5 (2C), 34.5 (2C), 34.4 (2C), 31.8 (2C), 29.6 (2C), 29.4 (2C), 29.1 (2C), 26.3 (2C), 25.0 (2C), 24.6 (2C), 22.2 (2C), 20.5 (2C), 19.0 (2C), 17.5 (2C), 15.5 (2C), 15.4 (2C); Anal. Calcd for  $\text{C}_{62}\text{H}_{92}\text{N}_2\text{O}_{14}\text{S}_2$ : C, 64.56; H, 8.04; N, 2.43. Found: C, 64.56; H, 8.04; N, 2.43. MS-ESI (MeOH)  $m/z$  (%) 1176.7 (100) ( $\text{MNa}^+$ ), 1154.0 (72) ( $\text{MH}^+$ );  $[\alpha]_{\text{D}}^{25} = -3.5$  (c 0.43,  $\text{CHCl}_3$ ); HRESI positive MS: Anal. Calcd for  $\text{C}_{62}\text{H}_{92}\text{N}_2\text{O}_{14}\text{S}_2\text{Na}^+$ , 1175.58822; found 1175.58942.

#### 4.3. Tubulin polymerization assay

Tubulin was isolated as pure  $\alpha\beta$ -tubulin (>95%) from fresh pig brain according to the protocol previously reported.<sup>6</sup> Tubulin was dissolved in BRB80 buffer (80 mM PIPES, 1 mM  $\text{MgCl}_2$ , 1 mM EGTA adjusted to pH 6.8 with KOH). Sample was diluted in BRB80 buffer to a final volume of 1 mL. Induction of polymerization of purified tubulin was determined in a centrifugation-based protein quantification assay. Compounds (5  $\mu\text{M}$  and 10  $\mu\text{M}$ ) were incubated with tubulin (5  $\mu\text{M}$ ) for 30 min at rt. The samples were subsequently centrifuged at 20,000g for 30 min at 4 °C and the protein concentration determined in the supernatant by the Bradford method (Biorad, Switzerland). The level of polymer formation upon incubation of compounds with purified tubulin was compared to the amount of polymerized tubulin induced with 25  $\mu\text{M}$  **Epo B**, which gave maximal polymerization >95%. The % tubulin polymerization values reported in Table 1 thus represent the ratio of polymer formation obtained with test compounds and 25  $\mu\text{M}$  **Epo B**, respectively. The % tubulin polymerization was determined in three independent experiments.

#### 4.4. Cell growth assay: A549 and MCF-7

$\text{IC}_{50}$  values for human cancer cell growth inhibition were determined for a 72 h exposure period of cells to compounds by quantification of protein content of fixed cells by methylene blue staining.<sup>14</sup> For further experimental details, see Nicolau et al.<sup>15</sup> The  $\text{EC}_{50}$  values given in the text and the  $\text{IC}_{50}$  values in the table all represent the means of three independent experiments ( $\pm$  standard deviation); **HT1080**: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Co., St. Louis, MO) dye reduction assay in 96-well microplates was used, as previously described.<sup>16</sup>  $3 \times 10^3$  BAE or  $2 \times 10^3$  HT1080 in a total volume of 100  $\mu\text{L}$  of their respective growth media were incubated with serial dilutions of the tested compounds. After 3 days of incubation (37 °C, 5%  $\text{CO}_2$  in a humid atmosphere) 10  $\mu\text{L}$  of MTT (5 mg/

mL in PBS) were added to each well and the plate was incubated for a further 4 h (37 °C). The resulting formazan was dissolved in 150  $\mu\text{L}$  of 0.04 N HCl-2 propanol and read at 550 nm. All determinations were carried out in triplicate.  $\text{IC}_{50}$  value was calculated as the concentration of compound yielding a 50% of cell survival.  **$\beta\text{D10}$** : Cells were harvested and plated in 96-well flat-bottomed microplates at a density of  $10^3$  cells/well. Assays were performed in quintuplicates. Cells were allowed to attach for 24 h. The drugs were prepared in medium at different concentrations and were added to the plates at a volume of 100  $\mu\text{L}$ /well. After 24 (or 96) h incubation 20  $\mu\text{L}$  of the CellTiter 96<sup>®</sup> AQ<sub>ueous</sub> one solution reagent (Promega Corporation, Madison, WI, USA) were added to each well and the plates were incubated for 1 h at 37 °C. The CellTiter 96<sup>®</sup> AQ<sub>ueous</sub> One Solution Reagent contains a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-nyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine ethosulfate; PES). PES has a high chemical stability, which allows it to form a stable solution with MTS. The absorbance was read at 490 nm on a plate spectrophotometer (Victor<sup>3</sup> 1420 Multilabel Counter, Perkin Elmer Instruments, Shelton, USA). Cell cytotoxicity was expressed as the percentage of the controls.

#### 4.5. Endothelial cell differentiation assay: tube formation on Matrigel

Matrigel (50  $\mu\text{L}$  of about 10.5 mg/mL) at 4 °C was used to coat each well of a 96-well plate and allowed to polymerize at 37 °C for a minimum of 30 min as described previously.<sup>12</sup> Some  $5 \times 10^4$  BAE cells were added with 200  $\mu\text{L}$  of DMEM. Finally, different amounts of the tested compounds were added and incubated at 37 °C in a humidified chamber with 5%  $\text{CO}_2$ . After incubation for 7 h, cultures were observed (200 $\times$  magnification) and photographed with a NIKON inverted microscope DIAPHOT-TMD (NIKON Corp., Tokyo, Japan). Each concentration was tested in duplicate, and two different observers evaluated the results of tube formation inhibition.

#### 4.6. Endothelial cell migration assay

The migratory activity of BAE cells was assessed using a wound migration assay.<sup>13</sup> Confluent monolayers in 6-well plates were wounded with pipette tips giving rise to one acellular 1 mm-wide lane per well. After washing, cells were supplied with 1.5 mL complete medium in the absence (controls) or presence of the indicated concentrations of the tested compounds. Wounded areas were photographed at zero time and after 7 and 24 h of incubation, plates were observed under microscope and photos were taken from the same areas as those recorded at zero time.

#### Acknowledgements

This research has been developed under the umbrella of CM 0602 COST Action 'Inhibitors of Angiogenesis: design, synthesis and biological exploitation'. The authors are grateful to NOVARTIS for providing Epothilone A. D. Passarella and D. Comi are grateful to the financial support provided by Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) PRIN 2007—Program 'Sviluppo e caratterizzazione di nuovi inibitori di tirosine chinasi cellulari con attività antiproliferativa e antiangiogenica nei confronti di differenti tumori'. A. R. Quesada is grateful to the financial support provided by Ministerio de Ciencia y Tecnología, Spain (CTQ2006-15279-C03-03) and Junta de Andalucía (Proyecto de investigación de excelencia CTS-3759).

## References and notes

1. (a) Nicolaou, K. C.; Roschangar, F.; Vourloumis, D. *Angew. Chem., Int. Ed.* **1998**, 37, 2014–2045; (b) Attard, G.; Greystoke, A.; Kaye, S.; De Bono, S. *Pathologie Biologie* **2006**, 54, 74–82.
2. (a) Höfle, G.; Bedorf, N.; Gerth, K. and Reichenbach, H.; German Patent Disclosure, DE 4138042, 1993 (Priority Nov. 19, 1991); *Chem. Abstr.* **1993**, 120, 52841.; (b) Gerth, K.; Bedorf, N.; Höfle, G.; Irschik, H.; Reichenbach, H. *J. Antibiot.* **1996**, 49, 560–564.
3. (a) Lee, F. Y. F.; Borzilleri, R.; Fairchild, C. R.; Kim, S.-H.; Long, B. H.; Reventos-Suarez, C.; Vite, G. D.; Rose, W. C.; Kramer, R. A. *Clin. Cancer Res.* **2001**, 7, 1429–1437; (b) Cortes, J.; Baselga, J. *Oncologist* **2007**, 12, 271–280; (c) Rivera, E.; Lee, J.; Davies, A. *Oncologist* **2008**, 13, 1207–1223; (d) Kaminskas, E.; Jiang, X.; Aziz, R.; Bullock, J.; Kasliwal, R.; Harapanhalli, R.; Pope, S.; Sridhara, R.; Leighton, J.; Booth, B.; Dagher, R.; Justice, R.; Pazdur, R. *Clin. Cancer Res.* **2008**, 14, 4378–4384; (e) Hunt, J. T. *Mol. Cancer Ther.* **2009**, 8, 275–281.
4. Thorpe, P. E.; Chaplin, D. J.; Blakey, D. C. *Cancer Res.* **2003**, 63, 1144–1147.
5. Jain, R. K. *Science* **2005**, 307, 58–62.
6. Gertsch, J.; Meyer, S.; Müller, M.; Altmann, K.-H. *ChemBioChem* **2009**, 10, 166–175.
7. Nicolaou, K. C.; Hepworth, D.; King, N. P.; Finlay, M. R. V.; Scarpelli, R.; Pereira, M. M. A.; Bollbuck, B.; Bogot, A.; Werschkun, B.; Winsigger, N. *Chem. Eur. J.* **2000**, 6, 2783–2800.
8. For other epothilones analogues see: (a) Nicolaou, K. C.; Scarpelli, R.; Bollbuck, B.; Werschkun, B.; Pereira, M. M.; Wartmann, M.; Altmann, K.-H.; Zaharevitz, D.; Gussio, R.; Giannakakou, P. *Chem. Biol.* **2000**, 7, 593–599; (b) Watkins, E. B.; Chittiboyina, A. G.; Jung, J. C.; Avery, M. A. *Curr. Pharm. Design* **2005**, 11, 1615–1653.
9. For other example of selective functionalization of C7–OH see: Sefkoe, M.; Kiffe, M.; Schummer, D.; Höfle, G. *Bioorg. Med. Chem. Lett.* **1998**, 8, 3025–3030.
10. Reamon-Buettner, S. M.; Borlak, J. *Cancer Res.* **2008**, 68, 7587–7596.
11. Folkman, J. *Nat. Med.* **1995**, 1, 27–31.
12. Rodríguez-Nieto, S.; Chavarría, T.; Martínez-Poveda, B.; Sánchez-Jiménez, F.; Quesada, A. R.; Medina, M. A. *Biochem. Biophys. Res. Commun.* **2002**, 293, 497–500.
13. Martínez-Poveda, B.; Quesada, A. R.; Medina, M. A. *Eur. J. Pharm.* **2005**, 516, 97–103.
14. Meyer, T.; Regenass, U.; Fabbro, D.; Alteri, E.; Rösel, J.; Müller, M.; Caravatti, G.; Matter, A. *Int. J. Cancer* **1989**, 43, 851–856.
15. Nicolaou, K. C.; Scarpelli, R.; Bollbuck, B.; Werschkun, B.; Pereira, M. M.; Wartmann, M.; Altmann, K.-H.; Zaharevitz, D.; Gussio, R.; Giannakakou, P. *Chem. Biol.* **2000**, 7, 593–599.
16. Rodríguez-Nieto, S.; Medina, M. A.; Quesada, A. R. *Anticancer Res.* **2001**, 21, 3457–3460.